Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Deborah A. Flusberg"'
Autor:
Benjamin O. Murray, Carlos Flores, Corin Williams, Deborah A. Flusberg, Elizabeth E. Marr, Karolina M. Kwiatkowska, Joseph L. Charest, Brett C. Isenberg, Jennifer L. Rohn
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
Urinary tract infections (UTIs) are among the most common infectious diseases worldwide but are significantly understudied. Uropathogenic E. coli (UPEC) accounts for a significant proportion of UTI, but a large number of other species can infect the
Externí odkaz:
https://doaj.org/article/9dc100b7beb5465f9bb36dd83b29aeb6
Autor:
Marissa Renardy, Alexander J. Prokopienko, Joseph R. Maxwell, Deborah A. Flusberg, Sahak Makaryan, Jangir Selimkhanov, Majid Vakilynejad, Kalyanasundaram Subramanian, Lucia Wille
Publikováno v:
Clinical Pharmacology & Therapeutics.
Autor:
Michaela Welch, Deborah A. Flusberg, Peter Hsi, Nerses J. Haroutunian, Jose A. Santos, Ernest S. Kim, Stacey Markovic, Jonathan R. Coppeta, Charles A. Lissandrello, Jenna L. Balestrini, Vishal Tandon
Publikováno v:
Advanced Materials Technologies.
Autor:
Daniel K. Freeman, Vienna L. Mott, Nerses J. Haroutunian, Jenna L. Balestrini, Vishal Tandon, Ernest S. Kim, Andrew Czarnecki, Charles A Lissandrello, Aaron G Stoddard, Michaela Welch, Peter Hsi, Jonathan R. Coppeta, Jordan P. Chesin, Jose A. Santos, Deborah A Flusberg
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Scientific Reports
Scientific Reports
Implementation of gene editing technologies such as CRISPR/Cas9 in the manufacture of novel cell-based therapeutics has the potential to enable highly-targeted, stable, and persistent genome modifications without the use of viral vectors. Electropora
Autor:
Graham Smith, Elliott B. Nickbarg, Chad Chamberlin, Noreen F. Rizvi, Christine Andrews, Victoria Kutilek, Peter Saradjian, Brooke M Swalm, Jennifer O'Neil, Patrick J. Curran, Peter J. Dandliker, Sam Kattar, Deborah A Flusberg
Publikováno v:
SLAS discovery : advancing life sciences RD. 24(2)
The Myc oncogene is overexpressed in many cancers, yet targeting it for cancer therapy has remained elusive. One strategy for inhibition of Myc expression is through stabilization of the G-quadruplex (G4), a G-rich DNA secondary structure found withi
Autor:
Peter K. Sorger, Deborah A Flusberg
Publikováno v:
Trends in cell biology. 25(8)
Tissue development and homeostasis are regulated by opposing pro-survival and pro-death signals. An interesting feature of the Tumor Necrosis Factor (TNF) family of ligands is that they simultaneously activate opposing signals within a single cell vi
Autor:
Aayush S. Agarwal, S Wanningen, Tugba Bagci-Onder, Peter K. Sorger, Deborah A Flusberg, Khalid Shah
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis specifically in tumor cells and its efficacy has been tested in pre-clinical models by delivering it systemically as a purified ligand or via engineered stem cells (SC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::324376abd0cfaeae67bcc74f2ebd827b
https://europepmc.org/articles/PMC3676868/
https://europepmc.org/articles/PMC3676868/
Autor:
Suzanne Gaudet, Hoda Eydgahi, Deborah A Flusberg, William W. Chen, Joshua J. Sims, Peter K. Sorger, Sabrina L. Spencer, Carlos F. Lopez, John A. Bachman
Publikováno v:
The FASEB Journal. 26
Autor:
Peter K. Sorger, Deborah A Flusberg
Publikováno v:
Physical Biology. 10:035002
TRAIL holds promise as an anti-cancer therapeutic but induces apoptosis in only a subset of tumor cell types. Moreover, many cancers that are responsive to TRAIL-mediated death exhibit partial sensitivity, with only a fraction of cells dying in respo
The mdm2 gene is a target for transcriptional activation by the p53 tumor suppressor gene product. Previous work has revealed that the mouse mdm2 gene contains two promoters: one is located upstream to the gene and is active in the absence of p53, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3545ad5de1714c38a6c13aca78d4e02
https://europepmc.org/articles/PMC307078/
https://europepmc.org/articles/PMC307078/